Background: CA 19-9 levels are useful for the diagnosis of patients with pancreatic adenocarcinoma. However, interest has recently turned toward its use as a prognostic indicator. The purpose of this study is to determine whether postoperative CA 19-9 levels predict disease-free survival (DFS) and median survival (MS) in patients after resection.
Methods: Between 1988 and 1996, 40 patients underwent resection for pancreatic adenocarcinoma and were evaluated with postoperative CA 19-9 assays. Eight patients had low preoperative levels of CA 19-9 (<2) and were excluded.
Results: CA 19-9 levels are good predictors of DFS and MS. Patients whose postoperative CA 19-9 values normalized by 3 to 6 months (<37 U/ml) had longer DFS (24 vs. 10 months,p<0.04) and MS (34 vs. 13 months,p<0.04). Patients with postoperative CA 19-9 values less than 180 U/ml at 1 to 3 months had a similar DFS (19 vs. 5 months,p<0.0009) and MS (34 vs. 13 months,p<0.0001) compared to patients with normal values at 3 to 6 months.
Conclusions: Postoperative measurements of CA 19-9 were the best predictors of DFS and MS. Values<180 U/ml at 3 months were as predictive as normal values by 3 to 6 months postoperatively. Consequently, CA 19-9 levels should be obtained for use as a stratification parameter in phase III trials.
Adenocarcinoma Pancreas Resection CA 19-9 Prognosis Recurrence
Parker SL, Tong T, Bolden S and Wingo PA. Cancer statistics.CA C J Clin 1996;46:5–27.Google Scholar
Gudjonsson B. Cancer of the pancreas. 50 years of surgery.Cancer 1987;60:2284–2303.PubMedGoogle Scholar
Trede M, Schwall G, Saeger HD. Survival after pancreaticoduodenectomy. 118 consecutive resections without an operative mortality.Ann Surg 1990;211:447–58.PubMedGoogle Scholar
Cameron JL, Crist DW, Sitzmann JV, Hruban RH, Boitnott JK, Seidler AJ, Coleman J. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer.Am J Surg 1991;161:120–5.CrossRefPubMedGoogle Scholar
Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen.Am J Gastroenterol 1990;85:350–5.PubMedGoogle Scholar
Magnani JL, Steplewski Z, Koprowski H, Ginsberg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin.Cancer Res 1983;43:5489–92.PubMedGoogle Scholar
Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.Cancer Res 1987;47:5501–3.PubMedGoogle Scholar
Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies.Somat Cell Mol Genet 1979;5:957–71.CrossRefGoogle Scholar
Del Villano BC, Brennan S, Brock P, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9.Clin Chem 1983;29:549–52.PubMedGoogle Scholar
Haglunde C, Roberts PJ, Kuusela P, Scheinin TM, Makela O, Jalanko H. Evaluation of CA 19-9 as a serum tumor marker in pancreatic cancer.Br J Cancer 1986;53:197–202.Google Scholar
Satake K, Chung YS, Umeyama K, Takeuchi T, Kim YS. The possibility of diagnosing small pancreatic cancer (less than 4.0 cm) by measuring various serum tumor markers.Cancer 1991;68:149–52.PubMedGoogle Scholar
Glenn J, Steinberg WM, Kurtzman SH, Steinberg S, Sindelar WF. Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the Pancreas.J Clin Oncol 1988;6:462–8.PubMedGoogle Scholar
Sperti C, Pasquali C, Catalini S, Cappellazzo F, Bonadimani B, Behboo R, Pedrazzoli S. CA 19-9 as a prognostic index after resection for pancreatic cancer.J Surg Oncol 1993;52:137–41.PubMedGoogle Scholar
Beretta E, Malesci A, Zerbi A, et al. Serum CA 19-9 in the post-surgical follow-up of patients with pancreatic cancer.Cancer 1987;60:2428–31.PubMedGoogle Scholar
Ishikawa O, Ohigashi H, Imaoka S, et al. Preoperative indications for extended pancreatectomy for locally advanced pancreas cancer involving the portal vein.Ann Surg 1992;215:231–6.PubMedGoogle Scholar
American Joint Committee on Cancer. Exocrine pancreas. In: Manual for Staging of Cancer, 4th ed. Philadelphia: JB Lippincott, 1992:109–11.Google Scholar
Hoffman JP, Weese JL, Solin LJ, et al. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas.Am J Surg 1995;169:71–8.CrossRefPubMedGoogle Scholar
Hoffman JP, Weese JL, Lipsitz S, Solin LJ, Benson AB III, Pisansky TM, Dalton A. Preoperative chemoradiation for patients with resectable pancreatic adenocarcinoma. An Eastern Cooperative Oncology Group (ECOG) phase II study.Proc Am Soc Clin Oncol 1995;14:201. Abstract.Google Scholar
Winek T, Hamre D, Mozell E, Vetto M. Prognostic factors for survival after pancreaticoduodenectomy for malignant disease.Am J Surg 1990;159:454–6.PubMedGoogle Scholar
Moossa AR, Levin B. The diagnosis of “early” pancreatic cancer: The University of Chicago experience.Cancer 1981;47:1688–97.PubMedGoogle Scholar
Pearce S, Thornes H, Carr D, Tanner A. Diagnostic pitfall: interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction.Gut 1994;35:707–8.PubMedGoogle Scholar
Willett CG, Daley WJ, Warshaw AL. CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer.Am J Surg 1996;172:350–2.CrossRefPubMedGoogle Scholar
Lundin J, Roberts PJ, Kuusela P, Haglund C. Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9.Anticancer Res 1995;15:2181–6.PubMedGoogle Scholar
van den Bosch RP, van Eijck CHJ, Mulder PGH, Jeekel J. Serum CA 19-9 determination in the management of pancreatic cancer.Hepatogastroenterology 1996;43:710–3.PubMedGoogle Scholar
Pohl AL. Surveillance of cancer patients with tumor markers.J Tumor Marker Oncol 1987;2(1):1–12.Google Scholar